Drug intelligence / Profile preview

Allogeneic CD70-targeting CAR-T cells

Development stage: Phase 1
Lead developer: CRISPR Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intrathecal

Overview

Allogeneic CD70-targeting CAR-T cells is an investigational cell therapy being developed for the treatment of relapsed or refractory CD70-positive brain gliomas. This therapy utilizes T cells derived from healthy adult donors (allogeneic) which are genetically engineered to express a chimeric antigen receptor (CAR) specific for the CD70 antigen, a member of the tumor necrosis factor superfamily frequently overexpressed in various malignancies, including high-grade gliomas. By targeting CD70, the CAR-T cells are designed to selectively identify and eliminate glioma cells. In clinical study, the cells are administered intrathecally to facilitate direct access to the central nervous system and overcome the limitations of the blood-brain barrier.

Other names: CAR-T-JIANG LONGWEI-gliomaAllogeneic CD70 CAR-T

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on Allogeneic CD70-targeting CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allogeneic CD70-targeting CAR-T cells.

Explore the full profile